We are live on ! Find out more
PRVL

Prevail Therapeutics
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

76 hedge funds and large institutions have $303M invested in Prevail Therapeutics in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

45% more capital inflows, than outflows

Capital inflows: $56.2M | Capital outflows: $38.8M

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

13% more funds holding

Funds holding: 67 → 76 (+9)

4.23% more ownership

Funds ownership: 82.62% → 86.85% (+4.2%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
76
Holders Change
+9
Holders Change %
+13.43%
% of All Funds
1.53%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
23
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PRVL Hedge Fund Activity: Q3 2020 in Review

76 of the 4,973 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics (PRVL) for Q3 2020, worth a combined $303M — down 28% from $421M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PRVL positions and 11 closed out — a net gain of 9 holders — while 23 added to existing stakes and 18 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.3M sold.

  • 76 institutional investors held Prevail Therapeutics (PRVL) as of Q3 2020, up from 67 in Q2 2020.
  • Funds reported $303M of Prevail Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
  • 20 funds opened new Prevail Therapeutics positions in Q3 2020 and 11 closed out, a net change of +9 holders.
  • The largest Prevail Therapeutics buyer in Q3 2020 was Citadel Advisors, an estimated $16.6M added.
  • The largest Prevail Therapeutics seller in Q3 2020 was Avidity Partners Management, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2020.